Related Experiment Videos
Conivaptan Yamanouchi.
1Doggrell Biomedical Communications, 47 Caronia Crescent, Lynfield, Auckland, New Zealand. s.doggrell@xtra.co.nz
Current Opinion in Investigational Drugs (London, England : 2000)
|April 9, 2005
Summary
Conivaptan, a vasopressin antagonist, offers aquaretic effects for treating hyponatremia and heart failure. The FDA approved injectable conivaptan for hyponatremia, requesting further safety data.
Area of Science:
- Pharmacology
- Nephrology
- Cardiology
Background:
- Vasopressin plays a key role in regulating water balance.
- Hyponatremia and heart failure are conditions often associated with fluid imbalance.
- Vasopressin V1a and V2 receptor antagonism offers a therapeutic target.
Purpose of the Study:
- To evaluate conivaptan as a potential treatment for hyponatremia and heart failure.
- To assess the aquaretic and V1a/V2 antagonistic properties of conivaptan.
Main Methods:
- Development of injectable conivaptan by Yamanouchi.
- Submission of a New Drug Application (NDA) to the US FDA.
- FDA review process for drug approval.
Main Results:
- Conivaptan demonstrates diuretic and aquaretic effects.
- FDA approval granted for injectable conivaptan for hyponatremia treatment.
- Additional safety data were requested by the FDA post-approval.
Conclusions:
- Conivaptan is an approved treatment for hyponatremia.
- Further safety evaluations are ongoing for conivaptan.
- Conivaptan represents a novel therapeutic approach for fluid balance disorders.